Stockscreener 앱 받기
34.75
3.47%
-1.25
시장 영업 전:
35.75
1.00
+2.88%
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
SION Q1 2026 Earnings: Wider Loss Surprises as Clinical Progress ContinuesFinal Results - newsline.com
Sionna Therapeutics - The Business Journals
Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price Returns - Yahoo Finance
Transcript : Sionna Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Sionna Therapeutics (SION) Gains 1.81% as Biotech Sentiment ImprovesAdaptive Moving Average - newsline.com
SION Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces Investor SkepticismGrowth Acceleration Report - newsline.com
Biotech Sionna Therapeutics at Jefferies and Goldman Sachs in June - Stock Titan
Sionna Therapeutics director Peter Thompson sells $4,493 of shares - Investing.com India
Sionna Therapeutics director Peter Thompson sells $4,493 of shares By Investing.com - Investing.com South Africa
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock - Investing.com
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock By Investing.com - Investing.com UK
Form 144 | Sionna Therapeutics(SION.US) Insider Proposes to Sell 46.33 Million in Common Stocks - Moomoo
Sionna Therapeutics (SION) Sees Slight Decline Amidst Key Support TestPre-Earnings Momentum - The Legal Advocate
SIONSionna Therapeutics Inc. stock news, filings & ratings - Quantisnow
Sionna Therapeutics (SION) Edges Higher as Biotech Sentiment Improves — Testing Key ResistanceAdvance Decline Volume - thelegaladvocate.com
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences - markets.businessinsider.com
SION Reiterates by Citizens -- Price Target Maintained at $63 - GuruFocus
Stifel Nicolaus Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data - Investing.com
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential By Investing.com - Investing.com Canada
SION Q1 2026 Earnings: Clinical-Stage Biotech Misses Estimates with Wider Net LossEarnings Growth Forecast - newsline.com
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $50 to $63 - Moomoo
Freedom Broker downgrades Sionna Therapeutics (SION) - MSN
Sionna Therapeutics Cut to Hold From Buy by Freedom Broker - Moomoo
SION: Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy - TradingView
Sionna Therapeutics Price Target Maintained With a $38.00/Share by Freedom Broker - Moomoo
Sionna Therapeutics stock rating cut to Hold at Freedom Broker By Investing.com - Investing.com Canada
SION Maintained by Stifel -- Price Target Raised to $55 - GuruFocus
Sionna Therapeutics Price Target Raised to $55.00/Share From $44.00 by Stifel - Moomoo
Wedbush Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Stifel raises Sionna Therapeutics price target on NBD1 data confidence By Investing.com - Investing.com Canada
Sionna Therapeutics (SION) Stock: Slides -0.80%, Support at $37.90 2026-05-18Strangle Setup - newsline.com
User - FinancialContent
Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN
Sionna Therapeutics, Inc. $SION Shares Purchased by Vanguard Group Inc. - MarketBeat
Sionna Therapeutics Develops Next-Generation Cystic Fibrosis Modulators - HarianBasis.co
RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Wedbush Initiates Coverage of Sionna Therapeutics (SION) - Insider Monkey
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout - TipRanks
LifeSci Capital Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Sionna Therapeutics Q1 Net Loss Narrows - Moomoo
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.4% on Disappointing Earnings - MarketBeat
Guggenheim reiterates Sionna Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Sionna stock ahead of summer data - Investing.com
1.27%
1.43%
자본화:
|
볼륨(24시간):